2013 Annual Report
1a.Objectives (from AD-416):
The main objective is to understand the molecular basis of the pathogenesis and immune response during the infection with African Swine Fever virus (ASFV). It is expected to gain knowledge to allow the development of experimental immunogens.
1b.Approach (from AD-416):
1) Evaluate the effect of specific ASFV genes as immunogens in the induction of protection against the challenge with virulent virus.
2) Evaluate the interaction of ASFV genes previously involved in virus virulence with host swine proteins.
3) Evaluate the effect of chemical compounds, which have demonstrated effect in the virus growth in vitro, in the pathogenesis of the disease in swine.
This research project seeks to develop an adjuvant-free antigen-delivery system utilizing subunit Classical Swine Fever Virus vaccine based on the glycoprotein E2 fused to the adjuvant molecule targeting to the antigen-presenting cells expressed in insect larvae using baculovirus as an expression vector. During FY 2012 researchers from INIA designed and developed the recombinant baculoviruses. Those viruses were further transferred to ARS PIADC where recombinant proteins were expressed as fusion products which were further purified by affinity chromatography. Due to the complexity of the genetic constructs to be expressed the process of antigen purification need to be adjusted to the individual constructs. Initial immunization trials were performed in FY 2013 with different protein doses and routes.
No technologies were transferred or publication resulted during FY 2013.